Saturday 6 August 2011

REVELOL Am (metoprolol+amlodipine) :: strengths: 50/5,25/2.5,25/5

 Efficacy and tolerability of a fixed-dose combination of metoprolol extended release/amlodipine in patients with mild-to-moderate hypertension:  Clin Drug Investig. 2010;30(2):123-31. Pareek A, Chandurkar NB, Sharma R, Tiwari D, Gupta BS.  

Abstract
Background
Epidemiological studies and clinical trials have shown that prevention of cardiovascular disease, the ultimate goal of hypertension treatment, requires a sufficient reduction in blood pressure.
Objective
The primary objective of this study was to measure the mean decrease in systolic (SBP) and diastolic (DBP) blood pressure with metoprolol extended release (XL)/amlodipine fixed-dose combination in patients with mild-to-moderate essential hypertension. The secondary objectives of this study were to evaluate the tolerability of the study medications.
Methods
This was a randomized, parallel-group, multicentre comparative study conducted at the outpatient departments of three teaching hospitals in India. Patients with mild-to-moderate hypertension (defined as DBP 90-109 mmHg) aged between 18 and 75 years were enrolled in this study and followed up for 12 weeks. Response to study treatments was evaluated in terms of mean decrease in SBP and DBP and the response rate (reduction to SBP <140 mmHg and DBP <90 mmHg).
Main outcome measures
Clinical assessment was done at screening, randomization, and at 2 weeks, 4 weeks and 8 weeks of treatment by calculating Western Ontario MacMaster (WOMAC) scores, time taken to walk 100 feet, visual analogue scores for pain, investigator's assessment on a Likert scale and joint tenderness. Tolerability assessment was based on adverse events. Patients compliance was also assessed.
Result
Out of 152 patients who underwent a 1-week placebo washout, 148 eligible patients were randomized to receive either metoprolol XL 25 mg/amlodipine 2.5 mg fixed-dose combination (76 patients) or losartan 25 mg plus amlodipine 2.5 mg (72 patients). The two treatment groups were similar with respect to demographic and baseline characteristics. Non-responders after 4 weeks of therapy were escalated to metoprolol XL 50 mg/amlodipine 5 mg fixed-dose combination or losartan 50 mg plus amlodipine 5 mg, respectively. The study was completed by 66 patients in each group, of whom 43 patients in each group responded to the starting doses. After 4 weeks' therapy, both treatments were associated with significant decreases in SBP and DBP from baseline (p < 0.001) and were comparable with respect to mean decrease in SBP (p = 0.304), mean decrease in DBP (p = 0.630) and response rate (p = 1.0). Also, both the step-up therapies were comparable with respect to mean decrease in SBP (p = 0.484), mean decrease in DBP (p = 0.650) and response rate (p = 0.134) at week 12. Both treatments were well tolerated in the studied population.
Conclusion
Metoprolol XL/amlodipine fixed-dose combination was found to be as effective and well tolerated as losartan plus amlodipine in the treatment of essential hypertension.
* courtesy : IPCA lab clinical research. 

Cardioplus details


ConstituentsPer Unit
Folic Acid300 mcg
Vit B121 mcg
Vit B61.5 mg
Vit A2500 iu
Vit C50 mg
Vit E400 iu
Selenium100 mcg
Zinc20 mg
Copper1 mg
Chromium (Chromic)70 mcg
Maganese1.5 mg

PRODUCT AT A GLANCE



CodeProduct DescriptionPackingDrug Name
34510ACE REVELOL 25/2.57TABMETOPROLOL SUCCINATE ER & RAMIPRIL TAB
34509ACE REVELOL 50/57TABMETOPROLOL SUCCINATE ER & RAMIPRIL TAB
33783CARDIOPLUS   10CAP ANTIOXIDANTS,VITAMINS,MINERALS
33790GLYCINORM 160 TAB10`SGLICLAZIDE
33788GLYCINORM 40 TAB10`SGLICLAZIDE
33789GLYCINORM 80 TAB10`SGLICLAZIDE
33791GLYCINORM M 30 MR TAB10`SGLICLAZIDE MODIFIED RELE METFORMIN HCLER
33786GLYCINORM M 40 TAB10`SGLICLAZIDE & METFORMIN HYDROCHLORIDE
33792GLYCINORM M 60 MR TAB10`SGLICLAZIDE MODIFIED RELE METFORMIN HCLER
33787GLYCINORM M 80 TAB10`SGLICLAZIDE & METFORMIN HYDROCHLORIDE
33836GLYCINORM OD 30 TABLET10 TABgliclazide modified release tablets
33837GLYCINORM OD 60 TABLET10 TABgliclazide modified release tablets
33800METAGARD CR-35 TAB10TABTRIMETAZIDINE CONTROLLED RELEASE
33801METAGARD CR-60 TAB10TABTRIMETAZIDINE CONTROLLED RELEASE
33802METAGARD TAB10TABTRIMETAZIDINE HCL 20MG
33812RAMCOR 1.2510 CAPRAMIPRIL
33815RAMCOR 1010 CAPRAMIPRIL
33813RAMCOR 2.510 CAPRAMIPRIL
33814RAMCOR 510 CAPRAMIPRIL
33811RAMCOR H 2.510 TABRAMIPRIL+HYDROCHLOROTHIAZIDE
33810RAMCOR H 510 TABRAMIPRIL+HYDROCHLOROTHIAZIDE
33838REVELOL 25H10 TABMETOPROLO SUCCINATE ER & HYDROCHLOROTHIA
33839REVELOL 50H10 TABMETOPROLO SUCCINATE ER & HYDROCHLOROTHIA
33835REVELOL AM (25/2.5)7 TABMETOPROLOL SUCCINATE ER&AMLODIPINE
33834REVELOL AM (50/5)7 TABMETOPROLOL SUCCINATE ER&AMLODIPINE
33823REVELOL AM 25/510 TABMETOPROLOL SUCCINATE ER&AMLODIPINE
33818REVELOL XL 10010 TABmetoprolol succinate extended release ta
33840REVELOL XL 12.510 TABmetoprolol succinate extended release ta
33816REVELOL XL 2510 TABmetoprolol succinate extended release ta
33817REVELOL XL 5010 TABmetoprolol succinate extended release ta